Skip to main content

Table 1 Baseline characteristics by monthly IV iron dose category

From: Evaluating the effectiveness of IV iron dosing for anemia management in common clinical practice: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)

 

IV Iron (mg/mo, average over 3 months)a

p valueb

0

<300

≥300

Study sample

 Patients, N

2800

3749

2922

 

 Patients, %

30

40

30

 

 Region, row %

    

  North America

29

41

30

0.94

  Europe and Australia/New Zealand

30

37

32

0.94

Demographics

 Age, years

64.0

64.0

63.5

0.06

 BMI, kg/m2

27.0

27.5

27.9

<.01

 Male, %

57

58

58

0.47

 Black, within US only, %

33

31

29

<.01

 Duration on dialysis, years

4.7

4.1

3.0

<.01

 Catheter, %

25

29

39

<.01

Comorbidities, %:

 Diabetes

47

51

54

<.01

 Hypertension

85

83

84

0.53

 Coronary Heart Disease

37

36

35

0.16

 Cerebrovascular Disease

13

14

14

0.77

 Congestive Heart Failure

30

30

28

0.80

 Peripheral Vascular Disease

26

25

25

0.22

 Other Cardiovascular

25

25

26

0.59

 Cancer (non-skin)

13

11

13

0.87

 GI Bleed (within 12 months)

4

4

5

0.23

 Lung Disease

13

13

13

0.77

 Neurologic Disease

10

9

9

0.19

 Psychiatric Disorder

17

16

15

0.20

 Recurrent Cellulitis or Gangrene

9

10

9

0.89

Laboratory Values (at month 0)

 Albumin, g/dL

3.79

3.77

3.68

<.01

 Creatinine, mg/dL

8.3

8.0

7.5

<.01

 White Blood Cells, x 103/uL

7.0

7.0

7.2

<.01

 TSAT, %

31.5

29.0

23.8

<.01

 Ferritin, ng/mL

687

538

441

<.01

 Hemoglobin, g/dL

11.6

11.5

11.2

<.01

 CRP, mg/Lc

12.7

11.9

15.8

0.35

Medication Doses (3-month average)

 IV Iron, mg/month

0

170

523

 

 ESA, IV epoetin equivalent units/week

10759

11426

16101

<.01

  1. aValues in table are sample mean unless noted otherwise
  2. b p value for trend within row (across three iron dose categories), adjusted for region and accounting for facility clustering, using logistic model for dichotomous and linear mixed model for continuous measures
  3. cRestricted to facilities measuring CRP in at least 50% of their patients (all North American facilities excluded)